These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48 related articles for article (PubMed ID: 1796423)
1. Prothrombin fragment 1 + 2 and intensity of treatment with oral anticoagulants. Mannucci PM; Bottasso B; Tripodi A; Bianchi Bonomi A Thromb Haemost; 1991 Dec; 66(6):741. PubMed ID: 1796423 [No Abstract] [Full Text] [Related]
2. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment. D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163 [TBL] [Abstract][Full Text] [Related]
3. The use of prothrombin fragment F1+2 to monitor the effect of oral anticoagulation. Bruhn HD; Zurborn KH J Heart Valve Dis; 1995 Mar; 4(2):138-40. PubMed ID: 8556173 [TBL] [Abstract][Full Text] [Related]
4. Prothrombin fragment 1+2 during oral anticoagulation in congenital nephrotic syndrome. Mache CJ; Muntean W; Resch B; Ring E Pediatr Nephrol; 1998 Sep; 12(7):617. PubMed ID: 9761365 [No Abstract] [Full Text] [Related]
5. Association between prothrombin activation fragment (F1.2), cerebral ischemia (S-100beta) and international normalized ratio (INR) in patients with ventricular assisted devices. Joshi A; Magder LS; Kon Z; Kallam S; Kwon M; Sangrampurkar R; Pierson R; Poston R Interact Cardiovasc Thorac Surg; 2007 Jun; 6(3):323-7. PubMed ID: 17669856 [TBL] [Abstract][Full Text] [Related]
6. Intravenous and oral sulodexide versus coagulation activation markers in humans. Borawski J; Dubowski M; Rydzewska-Rosolowska A; Mysliwiec M Clin Appl Thromb Hemost; 2009 Oct; 15(5):596-8. PubMed ID: 19910295 [No Abstract] [Full Text] [Related]
7. Effect of fixed minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1 + 2 in patients with atrial fibrillation. Koefoed BG; Feddersen C; Gulløv AL; Petersen P Thromb Haemost; 1997 May; 77(5):845-8. PubMed ID: 9184390 [TBL] [Abstract][Full Text] [Related]
8. Changes of prothrombin fragment 1+2 (F 1+2) as a function of increasing intensity of oral anticoagulation--considerations on the suitability of F 1+2 to monitor oral anticoagulant treatment. Tripodi A; Cattaneo M; Molteni A; Cesana BM; Mannucci PM Thromb Haemost; 1998 Mar; 79(3):571-3. PubMed ID: 9531043 [TBL] [Abstract][Full Text] [Related]
9. Low-intensity warfarin reduces thrombin generation and fibrin turnover, but not low-grade inflammation, in men at risk of myocardial infarction. MacCallum PK; Rudnicka AR; Rumley A; Meade TW; Lowe GD Br J Haematol; 2004 Nov; 127(4):448-50. PubMed ID: 15521923 [TBL] [Abstract][Full Text] [Related]
10. Documentation of hypocoagulability by measurement of prothrombin fragment F 1 + 2 when introducing oral anticoagulant therapy. Bruhn HD; Liebsch J; Wagner C Thromb Res; 1992 Nov; 68(3):317-9. PubMed ID: 1471078 [No Abstract] [Full Text] [Related]
11. Harmonization of commercial ELISA methods for the measurement of prothrombin fragment 1.2: is it feasible? D'Angelo A; Della Valle P; Calori G; Galli L; Vigano D'Angelo S Thromb Haemost; 1995 Mar; 73(3):548; author reply 549-50. PubMed ID: 7667841 [No Abstract] [Full Text] [Related]
12. Evaluation of the prethrombotic state in pregnancy and in women using oral contraceptives. Levine AB; Teppa J; McGough B; Cowchock FS Contraception; 1996 May; 53(5):255-7. PubMed ID: 8724613 [TBL] [Abstract][Full Text] [Related]
13. Standardization of prothrombin fragment 1.2 measurement: effects of preanalytical variables and calibrator selection. Hursting MJ; Slaughter TF; Stead AG; Szewczyk KM; Witt DJ; Greenberg CS Arch Pathol Lab Med; 1998 Jan; 122(1):31-6. PubMed ID: 9448013 [TBL] [Abstract][Full Text] [Related]
14. [Evaluation of an enzyme-linked immunosorbent assay for the determination of prothrombin fragment F1.2 (Dade Prothrombin Fragment F1.2 ELISA: Baxter Diagnostics Inc., U.S.A.) using micro-titer plate]. Suzuki T; Amano K; Kuroso K; Fukutake K; Fujimaki M Rinsho Byori; 1993 Feb; 41(2):215-9. PubMed ID: 8361024 [TBL] [Abstract][Full Text] [Related]
15. [Value of molecular markers for administration of anticoagulant therapy after heart valve replacement]. Dahm M; Lotz J; Hafner G; Oelert H; Prellwitz W Z Kardiol; 1998; 87 Suppl 4():42-5. PubMed ID: 9857466 [TBL] [Abstract][Full Text] [Related]
16. Oral anticoagulants: old drugs with a promising future. D'Angelo A; Crippa L; Agazzi A; Della Valle P; Anzalone N; Garlando AM; D'Angelo SV Haematologica; 1995; 80(2 Suppl):92-101. PubMed ID: 7628778 [No Abstract] [Full Text] [Related]
17. Feasibility of personal prothrombin time measurement in anticoagulant treatment follow-up. Niiranen S; Lamminen H J Telemed Telecare; 2002; 8(6):359-60. PubMed ID: 12537925 [No Abstract] [Full Text] [Related]
18. Markers of hemostatic system activation in pulmonary embolism. Changes during and after cessation of anticoagulant treatment. de Raucourt E; Meyer G; Landais P; Gouaref Z; Morinet P; Monge F; Sors H; Fischer AM Blood Coagul Fibrinolysis; 2000 Apr; 11(3):249-53. PubMed ID: 10870805 [TBL] [Abstract][Full Text] [Related]
19. Left atrial thrombin generation and prothrombin fragment 1+2: authors' reply. Peverill RE; Smolich JJ Clin Sci (Lond); 2001 Apr; 100(4):419-20. PubMed ID: 11256981 [No Abstract] [Full Text] [Related]
20. [Studies on the assay method of protein C and changes of vitamin K dependent coagulation factors including protein C in the cases with warfarin treatment]. Sakuragawa N; Maeda M; Niwa C; Kondoh K; Kazama Y; Niwa M; Yamagishi R; Satoh S; Kondoh S; Takahashi K Rinsho Byori; 1986 Apr; 34(4):464-8. PubMed ID: 3755774 [No Abstract] [Full Text] [Related] [Next] [New Search]